Atrasentan (ABT-627, ATN) pharmacokinetics (PK) and endothelin-1 (ET-1) pharmacodynamics (PD) in a phase 2 study of patients with asymptomatic hormone-refractory prostate cancer (HRPC) Conclusions: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback